Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
- PMID: 18632652
- DOI: 10.1158/0008-5472.CAN-07-6494
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
Abstract
Recruitment of circulating natural killer (NK) cells into inflamed lymph nodes is known to provide a potent, IFN-gamma-dependent boost for Th1-polarized immune responses in mouse models. Such NK cell recruitment into draining lymph nodes is induced by certain s.c. injected adjuvants, including mature vaccine dendritic cells (DC), and is mediated by a CXCR3-dependent pathway. Here, we show that monocyte-derived immature human DCs stimulated with polyinosinic acid:polycytidylic acid, IFN-alpha, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IFN-gamma, alpha-type 1-polarized DC (alpha DC1), secrete profuse amounts of the CXCR3 ligand CXCL9/MIG and substantial amounts of CXCL10/IP-10 and CXCL11/I-TAC after withdrawal of maturation stimuli. In sharp contrast, no measurable production of these chemokines was found in DCs after maturation with the current gold standard maturation cocktail for human DC-based cancer vaccines consisting of TNF-alpha, IL-1 beta, IL-6, and prostaglandin-E(2) (PGE(2)-DC). PGE(2)-DCs preferentially produced the Th2 and regulatory T-cell-attracting chemokines CCL17/TARC and CCL22/MDC, whereas only marginal levels of these chemokines were produced by alpha DC1s. Functional studies in vitro showed that supernatants from mature alpha DC1s actively recruited CD3(-)CD56(+) NK cells and that adding anti-CXCL9/MIG antibodies to the alpha DC1 supernatant substantially reduced this recruitment. Finally, alpha DC1s were able to induce IFN-gamma production when cocultured with resting autologous NK cells, but only if concurrent CD40 ligation was provided. These novel findings indicate that injected human alpha DC1-based vaccines have the potential to recruit and activate NK cells during their arrival to draining lymph nodes and that this feature may be of relevance for efficient priming of Th1 cells and CTLs.
Similar articles
-
Interferon-gamma dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines.Vaccine. 2006 Nov 30;24(49-50):7087-94. doi: 10.1016/j.vaccine.2006.07.002. Epub 2006 Jul 18. Vaccine. 2006. PMID: 16889876
-
Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production.J Leukoc Biol. 2005 Oct;78(4):954-66. doi: 10.1189/jlb.0704383. Epub 2005 Aug 4. J Leukoc Biol. 2005. PMID: 16081597
-
Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.Vaccine. 2008 Jun 2;26(23):2824-32. doi: 10.1016/j.vaccine.2008.03.054. Epub 2008 Apr 11. Vaccine. 2008. PMID: 18450338
-
Helper role of NK cells during the induction of anticancer responses by dendritic cells.Mol Immunol. 2005 Feb;42(4):535-9. doi: 10.1016/j.molimm.2004.07.038. Mol Immunol. 2005. PMID: 15607810 Review.
-
Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines.Crit Rev Immunol. 2001;21(1-3):157-78. Crit Rev Immunol. 2001. PMID: 11642602 Review.
Cited by
-
Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.Oncoimmunology. 2012 Jul 1;1(4):448-457. doi: 10.4161/onci.19788. Oncoimmunology. 2012. PMID: 22754763 Free PMC article.
-
NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells.Ther Adv Med Oncol. 2019 Dec 11;11:1758835919891622. doi: 10.1177/1758835919891622. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31853267 Free PMC article.
-
Engineering dendritic cells to enhance cancer immunotherapy.Mol Ther. 2011 May;19(5):841-53. doi: 10.1038/mt.2011.57. Epub 2011 Apr 5. Mol Ther. 2011. PMID: 21468005 Free PMC article. Review.
-
Immunotherapy of cancer in 2012.CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. CA Cancer J Clin. 2012. PMID: 22576456 Free PMC article. Review.
-
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.Immunotargets Ther. 2014 Oct 6;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. Immunotargets Ther. 2014. PMID: 27471705 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials